Company profile: Acticor Biotech
1.1 - Company Overview
Company description
- Provider of biopharmaceutical development of glenzocimab, a humanized monoclonal antibody fragment targeting platelet GPVI with antithrombotic properties without increasing bleeding risk, for the acute phase of ischemic stroke. Runs clinical trials: ACTISAVE, ACTIMIS, and GREEN in stroke, LIBERATE in myocardial infarction, and GARDEN in SARS-CoV-2-related ARDS.
Products and services
- ACTISAVE: A phase 2/3 add-on therapy clinical study evaluating glenzocimab’s efficacy and safety with thrombolysis, with or without mechanical thrombectomy, during the acute phase of ischemic stroke
- Glenzocimab: A clinical-stage humanized monoclonal antibody fragment targeting human platelet glycoprotein GPVI, engineered for antithrombotic activity without increasing bleeding risk in ischemic stroke
- GREEN: A phase 2/3 assessment measuring the efficacy and safety of glenzocimab as an add-on therapy to mechanical thrombectomy for acute ischemic stroke
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acticor Biotech
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
AltPep
HQ: United States
Website
- Description: Provider of diagnostic and therapeutic solutions for amyloid diseases, including SOBA Diagnostics for early detection and SOBIN Therapeutics for early treatment by targeting toxic soluble oligomers; offerings also include anti-biofilm applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltPep company profile →
Interactive Motion Technologies
HQ: United States
Website
- Description: Provider of robotic solutions for patients with neurological conditions, offering evidence-based InMotion Robots developed from medical engineering research at MIT’s Newman Laboratory for Biomechanics and Human Rehabilitation, tested by leading medical centers worldwide for 10 years in over 40 studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Interactive Motion Technologies company profile →
Cynapsus Therapeutics
HQ: Canada
Website
- Description: Provider of healthcare, biotechnology, and pharmaceutical therapeutics focused on Parkinson's disease, developing non-injectable treatments including APL-130277, a fast-acting, easy-to-use sublingual thin film for on-demand management of OFF episodes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cynapsus Therapeutics company profile →
Rhythmlink
HQ: United States
Website
- Description: Provider of medical devices that deliver the important physical connection between patients and diagnostic equipment, and services including contract manufacturing (custom product development, manufacturing processes, quality assurance, regulatory management), custom packaging, private labeling, and custom products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rhythmlink company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acticor Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acticor Biotech
2.2 - Growth funds investing in similar companies to Acticor Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acticor Biotech
4.2 - Public trading comparable groups for Acticor Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →